CWA
ASND icon

CM Wealth Advisors’s Ascendis Pharma A/S ASND Stock Holding History

CM Wealth Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,674
Closed -$228K – 85
2024
Q1 		$228K Buy
+1,674
New +$239K 0.07% 161
2023
Q2 		– Sell
-17,254
Closed -$1.32M – 176
2023
Q1 		$1.32M Buy
+17,254
New +$1.97M 0.26% 105

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CM Wealth Advisors's ASND Position: Q2 2024 in Review

CM Wealth Advisors sold out of Ascendis Pharma A/S (ASND) in Q2 2024, closing a stake of 1,674 shares — an estimated $228K sold.

CM Wealth Advisors first reported a position in ASND in Q1 2023 and held it in 2 quarters. The position peaked at $1.32M in Q1 2023. 203 funds tracked by Wall St. Rank hold ASND as of Q2 2024.

  • CM Wealth Advisors reported no remaining Ascendis Pharma A/S position as of Q2 2024 after selling out during the quarter.
  • CM Wealth Advisors sold 1,674 Ascendis Pharma A/S shares in Q2 2024, an estimated $228K.
  • CM Wealth Advisors first reported a position in Ascendis Pharma A/S in Q1 2023 and held it in 2 quarters.
  • CM Wealth Advisors's Ascendis Pharma A/S position peaked at $1.32M in Q1 2023.
  • 203 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2024.

Based on CM Wealth Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.